BiotechTube
aBioBot

aBioBot

San Francisco, United States· Est.
abiobot.io
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

aBioBot operates at the intersection of laboratory automation and artificial intelligence, providing integrated robotic systems and software platforms designed to automate repetitive lab tasks and enhance data-driven decision-making in drug discovery. The company targets the growing need for efficiency and reproducibility in life sciences R&D, offering tools that reduce manual labor and experimental variability. By combining hardware and AI, aBioBot aims to become a key enabler for biotech and pharma companies seeking to modernize their research infrastructure. Its value proposition centers on accelerating the path from hypothesis to validated results.

Drug DeliveryAI / Machine Learning

Technology Platform

Integrated platform combining automated laboratory robots for physical task execution with an AI-driven software suite for experimental design, data analysis, and workflow optimization.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The accelerating digital transformation of biopharma R&D creates a large and growing demand for integrated automation and AI solutions.
High R&D costs and productivity pressures push companies to seek efficiency tools, opening doors for platform adoption.
Partnerships with large pharma or CROs for deployment and validation could provide rapid scale and credibility.

Risk Factors

Significant execution risk in developing and maintaining a complex hardware-software integrated system that meets the high-reliability standards of labs.
Facing intense competition from both established lab automation giants and nimble AI software startups.
Market adoption may be slow due to high capital costs, workflow disruption, and inherent conservatism in life sciences.

Competitive Landscape

aBioBot competes in a fragmented but increasingly crowded market. It faces competition from large, diversified life science tools companies (e.g., Thermo Fisher, Agilent, PerkinElmer) with broad automation offerings, pure-play AI/ML drug discovery software firms (e.g., Recursion, Exscientia, Insilico Medicine), and other robotics-focused lab automation startups. Its key differentiator is the tight integration of proprietary hardware and AI software into a single workflow solution.

More companies in AI / Machine Learning →More companies in United States →